Biobank.Cy Center of Excellence has advanced a drug delivery system that specifically targets triple-negative breast cancer cells while sparing the healthy ones during treatment. This dual-mode vehicle enables diagnosis and targeted therapies through correct ER, PR, and HER2 receptors. It reverts the standard chemotherapy’s low therapeutic index, severe side effects and absorption limitations with which currently the medical community struggles with. The product has been developed, tested, and patented and the in vitro and in vivo results show superior efficacy with minimal side effects.